Auxilium Announces Appointments To Enhance Leadership Team

Auxilium also announced today the appointment of Darrin Bryan as Vice President, Commercial Analytics, a newly created position.  The addition of this role is consistent with the Company's focus on excellence in execution and driving the successful commercialization of Auxilium's current and future pipeline.  The Company expects to benefit from Mr. Bryan's extensive background in sales and marketing   strategic analysis.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's prospects for profitability, success and growth; the Company's ability to maximize the value of its current products and product pipeline; the strength of the Company's market opportunity; the Company's future financial and operational performance; the Company's ability to commercialize its product pipeline; the Company's future market position; the creation of value for shareholders; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite.

« First ‹ Previous 1 2 3 Next › Last »